Form 4: NeuroPace Director R Scott Huennekens Granted Stock Options Valued at $13.15 Per Share

NeuroPace Inc. Director R Scott Huennekens was granted 8,745 stock options with an exercise price of $13.15, vesting over 12 months, as disclosed in a recent SEC Form 4 filing.

Summary

• R Scott Huennekens, a Director of NeuroPace Inc. (NPCE), was granted 8,745 stock options.
• The transaction date for this grant was June 6, 2025.
• The exercise price for these stock options is $13.15 per share.
• The options will vest in twelve equal consecutive monthly installments, contingent on Mr. Huennekens' continuous service.
• The expiration date for these stock options is June 5, 2035.
• Following this transaction, Mr. Huennekens beneficially owns 8,745 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 filing itself is a disclosure of a transaction rather than a strategic announcement, the grant of stock options to a director is a positive sign of continued alignment between management/board and shareholder interests. It's a routine event but reflects ongoing commitment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for attracting and retaining experienced board members in the medical device and technology sectors.

Future Outlook

The vesting schedule of the stock options, occurring in twelve equal consecutive monthly installments, indicates an expectation of the director's continued service to NeuroPace Inc. over the next year.

Industry Context

The granting of stock options to directors is a common form of non-cash compensation in the medical technology and biotechnology industries. It serves to align the interests of board members with the long-term performance of the company, a standard practice for attracting and retaining talent in a competitive sector like neuromodulation.

Comparison to Industry Standards

• Equity compensation for directors, such as stock options, is a widely adopted practice across the medical device and technology sectors, including companies like Medtronic, Boston Scientific, and Abbott Laboratories, which frequently use similar mechanisms to incentivize their board members.
• The vesting schedule over 12 months is a typical short-to-medium term incentive structure, comparable to those seen in other growth-oriented healthcare companies aiming to retain key leadership.

Related Party Transactions

• The grant of stock options to R Scott Huennekens, a Director of NeuroPace Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor future dilution if exercised, but primarily serves to align the director's interests with long-term shareholder value.
• Director (R Scott Huennekens): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The stock options will vest in twelve equal consecutive monthly installments, subject to the director's continuous service.

Key Dates

Keywords

NeuroPace, NPCE, stock option, director, insider transaction, equity compensation, Form 4, SEC filing, corporate governance